CVS Health Corporation (NYSE:CVS) is one of the 13 Most Undervalued Retail Stocks to Buy Right Now. On June 5, Wells Fargo analyst Stephen Baxter maintained a Buy rating on CVS Health Corporation (NYSE:CVS) and set a price target of $84.00.
The company’s fiscal Q1 2025 results support the Buy rating, with total revenues increasing by 7% compared to last year to $94.6 billion. Generated cash flow from operations for the quarter reached $4.6 billion.
A row of shelves in a retail pharmacy, demonstrating the variety of drugs and over-the-counter products.
CVS Health Corporation (NYSE:CVS) also reported GAAP diluted EPS of $1.41, up from $0.88 in the prior year, and adjusted EPS of $2.25 for fiscal Q1 2025, up from $1.31 in the prior year. This rise was attributed to growth in the operating results of the Health Care Benefits segment.
The company revised its GAAP diluted EPS guidance range to $4.23 to $4.43 from $4.58 to $4.83. CVS Health Corporation (NYSE:CVS) also raised its adjusted EPS guidance range to $6.00 to $6.20 from $5.75 to $6.00.
CVS Health Corporation (NYSE:CVS) is a health solutions company that operates in four segments: healthcare benefits, health services, pharmacy & consumer wellness, and corporate/other. Apart from being a prominent pharmacy chain, the company is one of the largest health insurers in the United States through its Aetna subsidiary’s operations.
While we acknowledge the potential of CVS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None.
Add Comment